SCHEMBL1144735

SCHEMBL1144735

COc1ccc(C)c2[nH]c(C(=O)O)cc12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.79
HPGD P15428 3/20 0.79
ALDH1A1 P00352 2/20 0.50
LMNA P02545 1/20 0.50
KMT2A Q03164 5/20 0.48
IDO1 P14902 4/20 0.47
TDO2 P48775 4/20 0.47
FBP1 P09467 1/20 0.46
GPR35 Q9HC97 1/20 0.44
MEN1 O00255 4/20 0.43
POLB P06746 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
MCL1 Q07820 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29824959 0.89 KDM4E (1.00) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL3602542 0.89 KDM4E (1.00) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL4407742 0.88 KDM4E (0.60) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL8320971 0.86 KDM4E (0.59) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL4145148 0.84 KDM4E (0.56) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL1850124 0.83 KDM4E (0.53) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL24113173 0.83 HPGD (0.77) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL20604842 0.83 HPGD (0.77) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL30310360 0.83 HPGD (0.77) KDM4EHPGDALDH1A1LMNAKMT2A
SCHEMBL1144591 0.83 KDM4E (0.77) KDM4EHPGDALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed
WO-2023275357-A1 CASPASE-2 INHIBITOR COMPOUNDS Kintsugi Therapeutics S.L. (ES) 2023-01-05 WO disclosed
EP-4112631-A1 CASPASE-2 INHIBITOR COMPOUNDS Kintsugi Therapeutics S.L. (ES) 2023-01-04 EP disclosed
EP-2952514-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2015-12-09 EP disclosed
US-9181252-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-11-10 US disclosed
EP-2297163-B1 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-08 EP disclosed
US-20150152109-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-06-04 US disclosed
EP-2632925-B1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER (US) 2015-05-27 EP disclosed
US-8993586-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-03-31 US disclosed
US-20150025098-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-01-22 US disclosed
US-8859773-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2014-10-14 US disclosed
EP-2632925-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2013-09-04 EP disclosed
US-8318762-B2 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-11-27 US disclosed
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC 2012-05-03 US disclosed
WO-2012056372-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-05-03 WO disclosed
EP-2297163-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2011-03-23 EP disclosed
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER, INC. (US) 2011-02-03 US disclosed
WO-2009144554-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS PFIZER, INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025098-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY KDM4E 2570/4885HPGD 619/4885ALDH1A1 158/4885
US-20150152109-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY KDM4E 2570/4885HPGD 619/4885ALDH1A1 158/4885
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY KDM4E 2570/4885HPGD 619/4885ALDH1A1 158/4885
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB KDM4E 4784/4885HPGD 2210/4885ALDH1A1 2330/4885
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB KDM4E 1055/4885HPGD 567/4885ALDH1A1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.